TuHURA Biosciences reported second-quarter 2026 Research and Development expenses of $6.6 million, reflecting increased clinical activity. The company anticipates initiating its Phase 1b/2 trial of VISTA in mutated NPM1 r/r AML in the second half of 2026.
Key Highlights
- TuHURA reported $6.6 million in research and development expenses for Q2 2026, up from $4.9 million in 2025.
- A $50 million Credit Facility from its largest Shareholder provides significant operating Capital through 2028.
- The company plans to initiate a Phase 1b/2 trial for VISTA targeting mutated NPM1 r/r AML in the latter half of 2026.
TuHURA Biosciences, Inc. (NASDAQ: HURA) announced its second-quarter financial results for the period ending June 30, 2026. The company reported research and development expenses of $6.6 million, an increase from $4.9 million in the same quarter of 2025. This rise reflects a boost in clinical development activities and highlights the company's ongoing commitment to advancing its therapeutic programs.
This increase in spending signifies TuHURA's push toward realizing its strategic milestones in the highly competitive immuno-oncology environment.
Financial Highlights
At the end of the second quarter, TuHURA's cash and cash equivalents stood at $1.0 million. Financing activities, however, yielded positive results, with net cash inflows increasing to $10.6 million, up from $8.1 million year-over-year. TuHURA received $0.3 million in gross proceeds from its ATM program in April 2026 and another $0.1 million in July 2026, further contributing to its financial position.
These figures underline the balance of cash inflows and outflows as TuHURA funds its ambitious research agenda and clinical trials.
Strategic Progress
The recent establishment of a $50 million term credit facility from its largest shareholder significantly enhances TuHURA's operational capacity. The credit line supports ongoing clinical development, bearing a 12% annual Interest Rate on drawn funds, due for repayment by April 21, 2031. The facility allows TuHURA to access necessary funds on an as-needed basis, providing flexibility and sufficient runway to achieve its strategic goals.
This substantial backing empowers the company to invest in critical programs aimed at addressing resistant cancers, which may lead to further advancements in immunotherapy.
Upcoming Milestones
In the second half of 2026, TuHURA plans to initiate its Phase 1b/2 trial of VISTA targeting mutated NPM1 r/r AML, which is a priority in the company's pipeline. The anticipated feedback from the FDA regarding safety and proceed status is important for this next phase. The company also expects to receive Orphan Drug designation for its products including IFx-2.0 in Merkel cell carcinoma (MCC).
Achieving these milestones will not only validate TuHURA's developmental strategies but also strengthen its market position in immuno-oncology as the company seeks to provide innovative treatment Options for patients.
Future Watch
Looking ahead, TuHURA's strategic focus is set on multiple initiatives with significant milestones expected in 2026 and 2027. This includes preliminary results from studies involving its lead candidate IFx-2.0 in combination with established therapies for MCC. As TuHURA advances its clinical programs, the company will be under close scrutiny from investors regarding its efficacy data and regulatory outcomes.
The next update on its planned Phase 1b/2 trial will be a critical opportunity for investors seeking insight into the progress of its innovative pipeline.
Peers Moving on This News
- Connect Biopharma Holdings Ltd (NASDAQ: CNTB) little changed
- Unicycive Therapeutics Inc (NASDAQ: UNCY) down 2.0%






Please wait processing your request...